Increase in Transaminase Levels Following the Use of Raltegravir in a Woman With a High HIV Viral Load at 35 Weeks of Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 1, 2013, Pages 68-72

  Renet, Sophie ^a,b   Closon, Aurélie ^a   Brochet, Marie Sophie ^a   Bussières, Jean François ^a,c   Boucher, Marc ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Pregnancy; Raltegravir; Transaminase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEFAZOLIN; COTRIMOXAZOLE; FERROUS SULFATE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; UREA; URIC ACID; ZIDOVUDINE; 2 PYRROLIDONE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIRTH WEIGHT; BLOATING; CASE REPORT; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CONTINUOUS INFUSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; INFANT; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; NEWBORN; PNEUMOCYSTOSIS; PREGNANT WOMAN; RWANDAN; SINGLE DRUG DOSE; SPINAL ANESTHESIA; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; VERTICAL TRANSMISSION; VIRUS LOAD; BLOOD; GESTATIONAL AGE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PYRROLIDINONES; VIRAL LOAD;

EID: 84887322262     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)31051-3     Document Type: Article

References (32)

1. Report on the global aids epidemic Joint United Nations Programme on HIV/AIDS, Accessed April 14, 2011. http://www.unaids.org/documents/20101123_GlobalReport%20em._pdf.
2. Krist A.H. Obstetric care in patients with HIV disease. Am Fam Physician 2001, 63(1):107. -16,121-22.
3. Watts D.H. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002, 346:1879-1891.
4. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants World Health Organisation, Accessed April 14, 2011. http://www.who.int/hiv/pub/mtct/advice/en/.
5. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States National Institutes of Health, November 5. http://www.aidsinfo.mh.gov/%20contentfiles/perinatalgl.pdf.
6. de Ruiter A., Mercey D., Anderson J., Chakraborty R., Clayden P., Foster G., et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008, 9:452-502.
7. Yeni P. Prise en charge médicale des personnes infectées par le VIH Accessed April 14, 2011. http://www.unals.org/docs/Rapport_2010_sur_la_%20prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf.
8. Brochet M.S. Prévention de la transmission du VIH au nouveau-né. MedActuel DPC 2010, 10:33-37.
9. Merck Canada Inc Isentress (raltegravir potassium), Feb 10. [Product monograph], Accessed 2012 Oct 31, 2012. http://www.merck.com/%20product/usa/pi_circulars/i/isentress/isentress_pi.pdf.
10. Boucher M. Society of Obstetrics and Gynaecology Infectious Diseases Committee. Mode of delivery for pregnant women infected by the Human Immunodeficiency Virus. SOGC Clinical Practice Guidelines, No. 101, April 2001. J Soc Obstet Gynaecol Can 2001, 23:348-350.
11. Burdge D.R., Money D.M., Forbes J.C., Walmsley S.L., Smaill F.M., Boucher M., et al. Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ 2003, 168:1683-1688.
12. Petra Study Team Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002, 359:1178-1186.
13. Guay L.A., Musoke P., Fleming T., Bagenda D., Allen M., Nakabiito C., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
14. Dorenbaum A., Cunningham C.K., Gelber R.D., Culnane M., Mofenson L., Britto P., et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002, 288:189-198.
15. Lockman S., Shapiro R.L., Smeaton L.M., Wester C., Thior I., Stevens L., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356(2):135-147.
16. Musiime V., Ssali F., Kayiwa J., Namala W., Kizito H., Kityo C., et al. Response to non-nucleoside reverse transcriptase inhibitor-based therapy in HIVinfected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009, 25(10):989-996.
17. MacLeod I.J., Rowley C.F., Thior I., Wester C., Makhema J., Essex M., et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010, 48(3):162-167.
18. Guidelines for the use of antiretroviral agents in pediatric HIV infection National Insitutes of Health, April 14, 2011. http://www.aidsinfo.nih.gov/contentfiles/pediatricguidelines.pdf.
19. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
20. Hughes A., Barber T., Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008, 57:1-10.
21. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007, 35:1657-1663.
22. Dickinson L., Khoo S., Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010, 85:176-189.
23. McKeown D.A., Rosenvinge M., Donaghy S., Sharland M., Holt D.W., Cormack I., et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010, 24:2416-2418.
24. Else L.J., Taylor S., Back D.J., Khoo S.H. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther 2011, 16:1139-1147.
25. Pinnetti C., Baroncelli S., Villani P., Fantoni M., Tozzi V., De Luca A., et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010, 65:2050-2052.
26. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
27. Papendorp S.G., van den Berk G.E. Preoperative use of raltegravir- containing regimen as induction therapy: very rapid decline of HIV-1 viral load. AIDS 2009, 23:739.
28. Taylor N., Touzeau V., Geit M., Gisinger M., Egle A., Greil R., et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS. 2011, 22:358-360.
29. Johnson M. Raltegravir use in special populations. Eur J Med Res 2009, 14(Suppl 3):43-46.
30. Jaworsky D., Thompson C., Yudin M.H., Bitnun A., Brophy J., Samson L., et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010, 15:677-680.
31. Common terminology criteria for adverse events (CTCAE) v4.0 National Institutes of Health, April 14, 2012. https://cabig.nci.mh.gov/News_Folder/CTCAE_v4.0Z.
32. Avner M., Finkelstein Y., Hackam D., Koren G. Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Paediatr Drugs 2007, 9:267-270.